Continuous Buprenorphine Delivery Effect in Streptozotocine-Induced Painful Diabetic Neuropathy in Rats

Journal of Pain

Volumn 10, Issue 9, 2009, Pages 961-968

  Canta, Annalisa ^a   Chiorazzi, Alessia ^a   Meregalli, Cristina ^a   Carozzi, Valentina ^a   Oggioni, Norberto ^a   Lauria, Giuseppe ^b   Lombardi, Raffaella ^b   Bianchi, Roberto ^c   Porretta Serapiglia, Carla ^c   Cavaletti, Guido ^a  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b DEPARTMENT OF NEUROSURGERY   (Italy)

^c MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

allodynia; buprenorphine; Diabetes; neuropathy; pain; rats

Indexed keywords

BUPRENORPHINE; GLUCOSE; STREPTOZOCIN;

ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR CHANGE; CONTROLLED STUDY; DIABETIC NEUROPATHY; GLUCOSE BLOOD LEVEL; HISTOPATHOLOGY; HYPERGLYCEMIA; MALE; MECHANICAL STIMULATION; NERVE CONDUCTION; NEUROPATHIC PAIN; NONHUMAN; PAIN THRESHOLD; RAT; THERMAL STIMULATION;

ACTION POTENTIALS; ANALGESICS, OPIOID; ANIMALS; BUPRENORPHINE; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEUROPATHIES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ELECTRODIAGNOSIS; HYPERALGESIA; INFUSION PUMPS, IMPLANTABLE; MALE; NEURAL CONDUCTION; PERIPHERAL NERVOUS SYSTEM; RATS; RATS, SPRAGUE-DAWLEY; TREATMENT OUTCOME;

EID: 68949214977     PISSN: 15265900     EISSN: 15288447     Source Type: Journal    
DOI: 10.1016/j.jpain.2009.04.003     Document Type: Article

References (47)

1. Bannwarth B. Risk-benefit assessment of opioids in chronic noncancer pain. Drug Saf 21 (1999) 283-296
2. Bianchi R., Buyukakilli B., Brines M., Savino C., Cavaletti G., Oggioni N., Lauria G., Borgna M., Lombardi R., Cimen B., Comelekoglu U., Kanik A., Tataroglu C., Cerami A., and Ghezzi P. Erythropoietin both protects from and reverses experimental diabetic neuropathy. Proc Natl Acad Sci U S A 101 (2004) 823-828
3. Bianchi R., Marini P., Merlini S., Fabris M., Triban C., Mussini E., and Fiori M.G. ATPase activity defects in alloxan-induced diabetic sciatic nerve recovered by ganglioside treatment. Diabetes 37 (1988) 1340-1345
4. Boger R.H. Renal impairment: A challenge for opioid treatment? The role of buprenorphine. Palliat Med 20 Suppl 1 (2006) s17-s23
5. Borgland S.L. Acute opioid receptor desensitization and tolerance: Is there a link?. Clin Exp Pharmacol Physiol 28 (2001) 147-154
6. Brase D.A. Is intracellular sodium involved in the mechanism of tolerance to opioid drugs?. Med Hypotheses 32 (1990) 161-167
7. Calcutt N.A., Freshwater J.D., and Mizisin A.P. Prevention of sensory disorders in diabetic Sprague-Dawley rats by aldose reductase inhibition or treatment with ciliary neurotrophic factor. Diabetologia 47 (2004) 718-724
8. Cavaletti G., Cavalletti E., Montaguti P., Oggioni N., De Negri O., and Tredici G. Effect on the peripheral nervous system of the short-term intravenous administration of paclitaxel in the rat. Neurotoxicology 18 (1997) 137-145
9. Cavaletti G., Fabbrica D., Minoia C., Frattola L., and Tredici G. Carboplatin toxic effects on the peripheral nervous system of the rat. Ann Oncol 9 (1998) 443-447
10. Courteix C., Eschalier A., and Lavarenne J. Streptozocin-induced diabetic rats: behavioural evidence for a model of chronic pain. Pain 53 (1993) 81-88
11. Cowan A. Buprenorphine: New pharmacological aspects. Int J Clin Pract Suppl 3-8 (2003) 23-24
12. Cowan A., Doxey J.C., and Harry E.J. The animal pharmacology of buprenorphine, an oripavine analgesic agent. Br J Pharmacol 60 (1977) 547-554
13. Cowan A., Lewis J.W., and Macfarlane I.R. Agonist and antagonist properties of buprenorphine, a new antinociceptive agent. Br J Pharmacol 60 (1977) 537-545
14. Debruyne D., Quentin T., Poisnel G., Lelong-Boulouard V., Barre L., and Coquerel A. Acute and chronic administration of clorazepate modifies the cell surface regulation of mu opioid receptors induced by buprenorphine in specific regions of the rat brain. Brain Res 1052 (2005) 222-231
15. Dellemijn P.L., and Vanneste J.A. Randomised double-blind active-placebo-controlled crossover trial of intravenous fentanyl in neuropathic pain. Lancet 349 (1997) 753-758
16. Dini D., Fassio T., Gottlieb A., and Gini M. [Controlled study of the analgesic effect and tolerability of buprenorphine in cancer patients]. Minerva Med 77 (1986) 93-104
17. Eisenberg E., McNicol E.D., and Carr D.B. Efficacy of mu-opioid agonists in the treatment of evoked neuropathic pain: Systematic review of randomized controlled trials. Eur J Pain 10 (2006) 667-676
18. Evans H.C., and Easthope S.E. Transdermal buprenorphine. Drugs 63 (2003) 1999-2010
19. Freye E., and Latasch L. [Development of opioid tolerance: Molecular mechanisms and clinical consequences]. Anasthesiol Intensivmed Notfallmed Schmerzther 38 (2003) 14-26
20. Grecksch G., Bartzsch K., Widera A., Becker A., Hollt V., and Koch T. Development of tolerance and sensitization to different opioid agonists in rats. Psychopharmacology (Berl) 186 (2006) 177-184
21. Harati Y., Gooch C., Swenson M., Edelman S., Greene D., Raskin P., Donofrio P., Cornblath D., Sachdeo R., Siu C.O., and Kamin M. Double-blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy. Neurology 50 (1998) 1842-1846
22. Hsu M.M., and Wong C.S. The roles of pain facilitatory systems in opioid tolerance. Acta Anaesthesiol Sin 38 (2000) 155-166
23. Kiguchi S., Imamura T., Ichikawa K., and Kojima M. Oxcarbazepine antinociception in animals with inflammatory pain or painful diabetic neuropathy. Clin Exp Pharmacol Physiol 31 (2004) 57-64
24. Kouya P.F., Hao J.X., and Xu X.J. Buprenorphine alleviates neuropathic pain-like behaviors in rats after spinal cord and peripheral nerve injury. Eur J Pharmacol 450 (2002) 49-53
25. Lauria G., Lombardi R., Borgna M., Penza P., Bianchi R., Savino C., Canta A., Nicolini G., Marmiroli P., and Cavaletti G. Intraepidermal nerve fiber density in rat foot pad: Neuropathologic-neurophysiologic correlation. J Periph Nerv Syst 10 (2005) 202-208
26. Lewis J.W., and Husbands S.M. The orvinols and related opioids: High affinity ligands with diverse efficacy profiles. Curr Pharm Des 10 (2004) 717-732
27. Likar R., and Sittl R. Transdermal buprenorphine for treating nociceptive and neuropathic pain: Four case studies. Anesth Analg 100 (2005) 781-785
28. Lowry O.H., Rosebrough N.J., Farr A.L., and Randall R.J. Protein measurement with the Folin phenol reagent. J Biol Chem 193 (1951) 265-275
29. Malcangio M., and Tomlinson D.R. A pharmacologic analysis of mechanical hyperalgesia in streptozotocin/diabetic rats. Pain 76 (1998) 151-157
30. Mao J., Price D.D., and Mayer D.J. Experimental mononeuropathy reduces the antinociceptive effects of morphine: Implications for common intracellular mechanisms involved in morphine tolerance and neuropathic pain. Pain 61 (1995) 353-364
31. Masocha W., Gonzalez L.G., Baeyens J.M., and Agil A. Mechanisms involved in morphine-induced activation of synaptosomal Na+,K+-ATPase. Brain Res 957 (2002) 311-319
32. McQuay H.J. Neuropathic pain: Evidence matters. Eur J Pain 6(Suppl A) (2002) 11-18
33. Motta E.M., Calixto J.B., and Rae G.A. Mechanical hyperalgesia induced by endothelin-1 in rats is mediated via phospholipase C, protein kinase C, and MAP kinases. Exp Biol Med (Maywood) 231 (2006) 1141-1145
34. Park I., Kim D., Song J., In C.H., Jeong S.W., Lee S.H., Min B., Lee D., and Kim S.O. Buprederm, a new transdermal delivery system of buprenorphine: Pharmacokinetic, efficacy and skin irritancy studies. Pharm Res 25 (2008) 1052-1062
35. Pergolizzi J., Boger R.H., Budd K., Dahan A., Erdine S., Hans G., Kress H.G., Langford R., Likar R., Raffa R.B., and Sacerdote P. Opioids and the management of chronic severe pain in the elderly: Consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pain Pract 8 (2008) 287-313
36. Picard P.R., Tramer M.R., McQuay H.J., and Moore R.A. Analgesic efficacy of peripheral opioids (all except intra-articular): A qualitative systematic review of randomised controlled trials. Pain 72 (1997) 309-318
37. Radbruch L., and Vielvoye-Kerkmeer A. Buprenorphine TDS: The clinical development rationale and results. Int J Clin Pract Suppl (2003) 15-18
38. Rossano C., De Luca L.F., Firetto V., and Fossi F. Activity and tolerability of buprenorphine after parenteral and sublingual administration. Clin Ther 5 (1982) 61-68
39. Rowbotham M.C., Twilling L., Davies P.S., Reisner L., Taylor K., and Mohr D. Oral opioid therapy for chronic peripheral and central neuropathic pain. N Engl J Med 348 (2003) 1223-1232
40. Sadee W., Rosenbaum J.S., and Herz A. Buprenorphine: Differential interaction with opiate receptor subtypes in vivo. J Pharmacol Exp Ther 223 (1982) 157-162
41. Said G. Diabetic neuropathy: A review. Nat Clin Pract Neurol 3 (2007) 331-340
42. Sittl R. Transdermal buprenorphine in the treatment of chronic pain. Expert Rev Neurother 5 (2005) 315-323
43. Sporer K.A. Buprenorphine: A primer for emergency physicians. Ann Emerg Med 43 (2004) 580-584
44. Strain E.C., Stitzer M.L., Liebson I.A., and Bigelow G.E. Comparison of buprenorphine and methadone in the treatment of opioid dependence. Am J Psychiatry 151 (1994) 1025-1030
45. Strain E.C., Stitzer M.L., Liebson I.A., and Bigelow G.E. Buprenorphine versus methadone in the treatment of opioid dependence: Self-reports, urinalysis, and addiction severity index. J Clin Psychopharmacol 16 (1996) 58-67
46. Sugimoto K., Rashid I.B., Shoji M., Suda T., and Yasujima M. Early changes in insulin receptor signaling and pain sensation in streptozotocin-induced diabetic neuropathy in rats. J Pain 9 (2008) 237-245
47. Vinik A.I., Park T.S., Stansberry K.B., and Pittenger G.L. Diabetic neuropathies. Diabetologia 43 (2000) 957-973